Corcept Therapeutics (CORT) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue reached $157.2 million, up from $146.8 million year-over-year, driven by record prescription growth despite early quarter pharmacy fulfillment issues; net income was $20.5 million, down from $27.8 million, with diluted EPS of $0.17 versus $0.25.

• Rapid growth in hypercortisolism screening and treatment, with Korlym prescriptions nearly doubling year-over-year, and relacorilant NDA accepted by FDA with a PDUFA date of December 30, 2025.

• Oncology pipeline advances with positive phase III ROSELLA results in platinum-resistant ovarian cancer, meeting PFS and interim OS endpoints; NDA submission planned next quarter.

• ALS: DAZALS Phase 2 did not meet primary endpoint, but exploratory analysis showed improved survival at 300 mg dose.

• Cash and investments totaled $570.8 million at March 31, 2025, reflecting strong liquidity and $43.3 million in stock repurchases.

Financial highlights

• Q1 2025 revenue: $157.2 million, up from $146.8 million in Q1 2024; 2024 revenue: $675 million; 2025 guidance: $900–950 million.

• Net income: $20.5 million, down from $27.8 million year-over-year; diluted EPS: $0.17, down from $0.25.

• Operating income dropped to $3.4 million from $29.5 million year-over-year due to higher R&D and SG&A expenses.

• Cash and investments as of March 31, 2025: $570.8 million.

• $43.3 million of common stock repurchased in Q1 2025.

Outlook and guidance

• 2025 revenue guidance reiterated at $900–950 million, supported by improved pharmacy operations, strong prescription trends, and new product launches.

• NDA for relacorilant in hypercortisolism expected to be approved by year-end; NDA for ovarian cancer submission planned for next quarter.

• Growth expected to accelerate in the second half of 2025, driven by increased screening, expanded sales force, and CATALYST study publication.

• Management anticipates funding operations and planned R&D activities over the next 12 months and beyond without needing to raise additional funds.

• Multiple clinical trial readouts and regulatory milestones anticipated through 2026.